Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis

Brain Research

Volumn 1381, Issue , 2011, Pages 243-253

  Rahn, Kristen A ^a   McLaughlin, Patricia J ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmune diseases; encephalomyelitis; Experimental autoimmune; Multiple sclerosis; Opioid; Opioid growth factor; Opioid growth factor receptor

Indexed keywords

METENKEPHALIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NALTREXONE; OPIATE; OPIATE ANTAGONIST;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; LOW DRUG DOSE; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL LESION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; STATISTICAL ANALYSIS;

ANALYSIS OF VARIANCE; ANIMALS; ASTROCYTES; CHI-SQUARE DISTRIBUTION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENKEPHALIN, METHIONINE; FEMALE; MICE; MICE, INBRED C57BL; MYELIN SHEATH; MYELIN-ASSOCIATED GLYCOPROTEIN; NALTREXONE; NEURONS;

ANIMALIA; MUS;

EID: 79952283348     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.01.036     Document Type: Article

References (53)

1. The Australia and New Zealand Sclerosis Genetics Consortium (ANZgene) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20 Nat. Genet. 41 2009 824 830
2. P. Bannerman, and A. Hahn Enhanced visualization of axon pathology in EAE using thy1-YFP transgenic mice J. Neurol. Sci. 260 2007 23 32 (Pubitemid 47225086)
3. P. Bannerman, A. Hahn, A. Soulika, V. Gallo, and D. Pleasure Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia Glia 55 2007 57 64 (Pubitemid 44845509)
4. J.L. Bennett, and O. Stuve Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications Clin. Neuropharm. 32 2009 121 132
5. 5]-enkephalin, is dependent on clathrin-mediated endocytosis to downregulate cell proliferation Amer. J. Physiol. Regul. Integr. Comp. Physiol. 299 2010 R774 R785
6. F. Cheng, I.S. Zagon, M.F. Verderame, and P.J. McLaughlin The OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck Cancer Res. 67 2007 10511 10518 (Pubitemid 350070827)
7. WAF1/CIP1 pathways to restrict normal cell proliferation Mol. Biol. Cell 20 2009 319 327
8. F. Cheng, P.J. McLaughlin, M.F. Verderame, and I.S. Zagon Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation Exp. Biol. Med. 234 2009 532 541
9. F. Cheng, P.J. McLaughlin, and I.S. Zagon Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin β and Ran for nucleocytoplasmic trafficking Exp. Biol. Med. 235 2010 1093 1101
10. B.A.C. Cree, E. Kornyeyeva, and D.S. Goodin Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis Ann. Neurol. 68 2010 145 150
11. K. Csontos, M. Rust, V. Hollt, W. Mahr, W. Kromer, and H.J. Teschemacher Elevated plasma β-endorphin levels in pregnant women and their neonates Life Sci. 25 1979 835 844 (Pubitemid 10229026)
12. C. Dass, and P. Mahalakshmi Phosphorylation of enkephalins enhances their proteolytic stability Life Sci. 58 1996 1039 1045 (Pubitemid 26088527)
13. J.A. Encinas, M.B. Lees, R.A. Sobel, C. Symonowicz, J.M. Greer, C.L. Shovlin, H.L. Weiner, C.E. Seidman, J.G. Seidman, and V.K. Kuchroo Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice J. Immunol. 157 1996 2186 2192 (Pubitemid 126449699)
14. A.M. Ercolini, and S.D. Miller Mechanisms of immunopathology in murine models of central nervous system demyelinating disease J. Immunol. 176 2006 3293 3298 (Pubitemid 43363973)
15. M. Forte, B.G. Gold, G. Marracci, P. Chaudhary, E. Basso, D. Johnsen, X. Yu, J. Fowlkes, M. Rahder, K. Stem, P. Bernardi, and D. Bourdette Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis Proc. Natl. Acad. Sci. USA 104 2007 7558 7563 (Pubitemid 47185945)
16. M. Gironi, V. Martinelli, E. Brambilla, R. Furlan, A.E. Panerai, G. Comi, and P. Sacerdote β-endorphin concentrations in peripheral blood mononuclear cells of patients with multiple sclerosis Arch. Neurol. 57 2000 1178 1181
17. M. Gironi, F. Martinelli-Boneschi, P. Sacerdote, C. Solaro, M. Zaffaroni, R. Cavarretta, L. Moiola, S. Bucello, M. Radaelli, V. Pilato, M.E. Rodegher, M. Cursi, S. Franchi, V. Martinelli, R. Nemni, G. Comi, and G. Martino A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis Mult. Scler. 14 2008 1076 1083
18. T. Isayama, and I.S. Zagon Localization of preproenkephalin A mRNA in the neonatal rat retina Brain Res. Bull. 27 1991 805 808
19. B.D. Jankovic Enkephalins and immune inflammatory reactions Acta Neurol. 13 1991 433 441
20. F. Leslie Methods used for the study of opioid receptors Pharmacol. Rev. 39 1987 197 249 (Pubitemid 18045485)
21. K.C. MacNamara, M.M. Chua, P.T. Nelson, H. Shen, and S.R. Weiss Increased epitope-specific CD8+ T cells prevent murine coronavirus spread to the spinal cord and subsequent demyelination J. Virol. 79 2005 3370 3381 (Pubitemid 40327925)
22. I. Milicevic, S. Pekovic, S. Subasic, M. Mostarica-Stojkovic, S. Stosic-Grujicic, L. Medic-Milacevic, V. Pejanovic, L. Rakic, and M. Stojiljkovic Ribavarin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats J. Neurosci. Res. 72 2003 268 278 (Pubitemid 36389894)
23. K. Pandey, and F.D. Lublin Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal Curr. Treat. Options Neurol. 11 2009 193 202
24. S.A. Rizvi, and M.A. Agius Current approved options for treating patients with multiple sclerosis Neurology 63 2004 S8 S14
25. B.F. Roy, C. Benkelfat, J.L. Hill, P.F. Pierce, M.M. Dauphin, T.M. Kelly, T. Sunderland, D.R. Weinberger, and N. Breslin Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection Biol. Psychiatry 35 1994 335 344 (Pubitemid 24150269)
26. N. Sharafaddinzadeh, A. Moghtaderi, D. Kashipazha, N. Majdinasab, and B. Shalbafan The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial Mult. Scler. 16 2010 964 969
27. R.L. Sidman Atlas of the Mouse Brain and Spinal Cord 1979 Harvard University Press Cambridge
28. J.P. Smith, M. Ahmad, R. Conter, S. Bingaman, H. Harvey, D. Mauger, L. Demers, P.J. McLaughlin, S. Stanley, and I.S. Zagon Treatment of advanced pancreatic cancer with opioid growth factor Anticancer Drugs 15 2004 203 209 (Pubitemid 38429411)
29. J.P. Smith, S.I. Bingaman, D.T. Mauger, H.A. Harvey, L.M. Demers, and I.S. Zagon Opioid growth factor (OGF) improves clinical benefit and survival in patients with advanced pancreatic cancer Open Access J. Clin. Trials 2 2010 37 48
30. J.P. Smith, H. Stock, S. Bingaman, D.T. Mauger, and I.S. Zagon Low dose naltrexone therapy improves Crohn's disease Amer. J. Gastroenterol. 102 2007 820 828 (Pubitemid 46496605)
31. C.C. Stichel, and H. Luebbert Inflammatory processes in the aging mouse brain Neurobiol. Aging 28 2007 1507 1521
32. W.E. Suen, C.M. Bergman, P. Hjelmstrom, and N.H. Ruddle A critical role for lymphotoxin in experimental allergic encephalomyelitis J. Exp. Med. 186 1997 1233 1240 (Pubitemid 27469018)
33. I. Tsunoda, Y. Wada, J.E. Libbey, T.S. Cannon, F.G. Whitby, and R.S. Fujinami Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B J. Virol. 75 2001 7494 7505 (Pubitemid 32738008)
34. A. Van der Walt, H. Butzkueven, S. Kolbe, M. Marriott, E. Alexandrou, M. Gresle, G. Egan, and T. Kilpatrick Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade Pharmacol. Therap. 126 2010 82 93
35. H.L. Weiner The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann. Neurol. 65 2009 239 248
36. I.S. Zagon, R.N. Donahue, R.H. Bonneau, and P.J. McLaughlin B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases Immunobiology 216 2011 173 183
37. 5]-enkephalin)-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology (epub ahead of print, Sept. 29, 2010).
38. I.S. Zagon, S.R. Goodman, and P.J. McLaughlin Characterization of zeta (ζ): a new opioid receptor involved in growth Brain Res. 482 1989 297 305 (Pubitemid 19066541)
39. I.S. Zagon, T. Isayama, and P.J. McLaughlin Preproenkephalin mRNA expression in the developing and adult rat brain Mol. Brain Res. 21 1994 85 98 (Pubitemid 24034913)
40. I.S. Zagon, and P.J. McLaughlin Naltrexone modulates tumor response in mice with neuroblastoma Science 221 1983 671 673 (Pubitemid 13026087)
41. I.S. Zagon, and P.J. McLaughlin Increased brain size and cellular content in infant rats treated with an opiate antagonist Science 221 1983 1179 1180 (Pubitemid 13001230)
42. I.S. Zagon, and P.J. McLaughlin Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer Life Sci. 35 1984 409 416 (Pubitemid 14083762)
43. I.S. Zagon, and P.J. McLaughlin Naloxone modulates body and organ growth of rats: dependency on the duration of opioid receptor blockade and stereospecificity Pharmacol. Biochem. Behav. 33 1989 325 328 (Pubitemid 19245514)
44. I.S. Zagon, and P.J. McLaughlin Endogenous opioids regulate growth of neural tumor cells in culture Brain Res. 490 1989 14 25 (Pubitemid 19154956)
45. I.S. Zagon, and P.J. McLaughlin Identification of opioid peptides regulating proliferation of neurons and glia in the developing nervous system Brain Res. 542 1991 318 323
46. 5]-enkephalin to acute opioid antagonist (naltrexone) exposure Mol. Brain Res. 33 1995 111 120
47. I.S. Zagon, K.A. Rahn, A.P. Turel, and P.J. McLaughlin Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis Exp. Biol. Med. 234 2009 1383 1392
48. I.S. Zagon, K.A. Rahn, Robert H. Bonneau, A.P. Turel, and P.J. McLaughlin Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis Brain Res. 1310 2010 154 161
49. I.S. Zagon, T.B. Ruth, A.E. Leure-duPree, J.W. Sassani, and P.J. McLaughlin Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea Brain Res. 967 2003 37 47 (Pubitemid 36324287)
50. I.S. Zagon, T.B. Ruth, and P.J. McLaughlin Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium Anat. Rec. 282A 2005 24 37 (Pubitemid 40076252)
51. I.S. Zagon, M.F. Verderame, S.S. Allen, and P.J. McLaughlin Cloning, sequencing, chromosomal location, and function of a cDNA encoding the opioid growth factor receptor (OGFr) in humans Brain Res. 856 2000 75 83 (Pubitemid 30085513)
52. J. Ziaber, Z. Baj, J. Pasnik, H. Chmielewski, and H. Tchorzewski Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple sclerosis Immunol. Lett. 71 2000 127 129 (Pubitemid 30089776)
53. J. Ziaber, J. Panik, Z. Baj, L. Pokoca, H. Chmielewski, and H. Tchorzewski The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis Mediat. Inflamm. 7 1999 335 338